SynBioBeta Speaker

Gleb Kuznetsov

Manifold Bio

Co-founder & CEO

Gleb Kuznetsov is Co-Founder and CEO of Manifold Bio, a company combining AI protein design with generation of biological data at massive scale and physiological relevance to build organism-scale models of biology for design of therapeutics. He founded Manifold Bio after completing his PhD in the Harvard Biophysics program in the lab of George Church, where he developed new approaches for protein measurement and design by combining high-throughput biology, DNA sequencing, DNA synthesis, and machine learning technologies.

Sessions Featuring

Gleb

This Year

Breakout Session

•

3:30 PM

-

4:15 PM

AIxBIO

Where Does Biology Compute? From Molecular Signals to Clinical Reality

As we move toward the “virtual cell” and ultimately the “virtual organism,” the AIxBIO ecosystem faces a fundamental challenge: where does biology actually compute? While our ability to measure molecular events has advanced dramatically, predicting how those signals translate into emergent, system-level outcomes remains a core bottleneck in programmable biology. This session brings together leaders across AI, synthetic biology, and medicine to explore the computational bottleneck, mapping where predictive power breaks down from molecules to cells to organisms. It will examine how to measure emergence at scale by generating causal, time-resolved, perturbation-rich datasets across diverse biological contexts, and how to close the reality gap with in vivo feedback, using next-generation sensors and real-world data to continuously calibrate and validate models in living systems.

Featuring

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Gleb Kuznetsov

Manifold Bio

Co-founder & CEO

Kim Branson

GlaxoSmithKline

SVP, Global Head

Drug-discovery AI architect turning data into medicines.

Micha Breakstone

Cellular Intelligence

Co-founder & CEO

Fabio Boniolo

Polyphron

CSO & Co-founder

Breakout Session

•

3:30 PM

-

4:15 PM

AIxBIO

Where Does Biology Compute? From Molecular Signals to Clinical Reality

As we move toward the “virtual cell” and ultimately the “virtual organism,” the AIxBIO ecosystem faces a fundamental challenge: where does biology actually compute? While our ability to measure molecular events has advanced dramatically, predicting how those signals translate into emergent, system-level outcomes remains a core bottleneck in programmable biology. This session brings together leaders across AI, synthetic biology, and medicine to explore the computational bottleneck, mapping where predictive power breaks down from molecules to cells to organisms. It will examine how to measure emergence at scale by generating causal, time-resolved, perturbation-rich datasets across diverse biological contexts, and how to close the reality gap with in vivo feedback, using next-generation sensors and real-world data to continuously calibrate and validate models in living systems.

Featuring

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Gleb Kuznetsov

Manifold Bio

Co-founder & CEO

Kim Branson

GlaxoSmithKline

SVP, Global Head

Drug-discovery AI architect turning data into medicines.

Micha Breakstone

Cellular Intelligence

Co-founder & CEO

Fabio Boniolo

Polyphron

CSO & Co-founder

Previous Speakers Include